Belgian telcos: Football rights negotiations between DAZN and Proximus resume. Eurocommercial Properties: CMD Feedback. EVS: Adds another small acquisition to its new ‘media robotics' segment. Kinepolis: Paramount Skydance reportedly to bid for Warner Bros. Discovery. Wolters Kluwer: Two CEOs, one strong AI story
Azelis: Highlights ING Benelux Conference London. Barco: Highlights ING Benelux Conference London. Kinepolis: Highlights ING Benelux Conference London. Melexis: Highlights ING Benelux Conference London. ABN AMRO: Dutch State reducing stake to 20%. ASML: x Mistral, a bet on A.I.. Kinepolis: Cineplex August 2025 box office revenue at 87% of 2019 level, down 27% YoY
Investors should Keep The Faith as Kinepolis Group showed resilience in 1H25, rebounding from a weak start with strong 2Q visitor growth and rising profitability, supported by premium formats. While the delay of the Michael biopic (originally planed for 3Q) deprived cinemas of a potential blockbuster boost, Kinepolis' management remains confident. Despite a challenging August and an uncertain 3Q outlook, a strong 4Q and FY26 pipeline offers hope for recovery. In the meantime, Kinepolis continues...
In this September update we added 2 stocks to the KBC Securities Dynamic Top Pick List : We added AB InBev after the share price weakened post-2Q results. ABI's 2Q volumes fell 1.9% organically, below expectations, mainly due to a 9% drop in Brazil where a price hike led to temporary market share loss. However, strong revenue per hl growth (+4.9%) drove a 6.5% organic EBITDA increase, with 1H growth at +7.2%, near the top of FY guidance (+4–8%). AB InBev, the world's largest brewer, generates ...
We up our EPS up 2%-1%, our target price remains unchanged. Kinepolis reported a strong 1H, on better operating leverage, higher ticket and ITS, slightly higher visitors while net debt was in line. We slightly cut our visitors estimates on a more prudent 3Q, but this is more than offset by higher spend per visitor and margins. The stock underperforms 22% YTD, as a too-bullish consensus was adjusting to a weaker attendance. We think the case is worth revisiting. The pure standalone recovery story...
In an update on the regulatory approval procedure in the US of Evoca, its first protein-based biocontrol product, Biotalys has received further guidance from EPA, the U.S. Environmental Protection Agency on the regulatory review of Evoca. The EPA has confirmed that the scientific review of the dossier is progressing, and that all the requests for additional information have been addressed. While the agency continues to work diligently on the review, Biotalys now expects the final steps of the re...
A director at Montea NV bought 2,000 shares at 69.980EUR and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.